Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Orexigen Therapeutics Stories

2008-10-03 12:00:27

Orexigen Therapeutics, a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, has initiated its first Phase IIa clinical trial with OREX-003, a proprietary sustained release formulation of zonisamide plus olanzapine. The Phase IIa clinical trial, OZ-101, is designed to examine the effectiveness of OREX-003 in mitigating drug-associated weight gain or other metabolic consequences commonly experienced by patients taking atypical...